程序性死亡分子-1及其配体在非小细胞肺癌中的治疗进展  

Progression of PD-1/PD-L1 in non-small cell lung cancer therapy

作　　者：王怡[1] 杨泽[1] 柏玉举[1] 马虎[1,2,3] WANG Yi YANG Ze BAI Yuju MA Hu(Department of Thoracic Onco!ogy, Affiliated Hospital of Zunyi Medical University, Guizhou Province, Zunyi 563000, China Biotherapy Talent Base of Guizhou Province, Guizhou Province, Zunyi 563000, China Center for Transla- tional Medicine, Zunyi Medical University, Guizhou Province, Zunyi 563000, China)

机构地区：[1]遵义医学院附属医院胸部肿瘤科,贵州遵义563000 [2]贵州省生物治疗人才基地,贵州遵义563000 [3]遵义医学院转化医学中心,贵州遵义563000

出　　处：《中国医药导报》2017年第15期39-42,54,共5页China Medical Herald

基　　金：国家自然科学基金资助项目(81360351);贵州省科技厅攻关项目(黔科合SY字[2013]3003号)

摘　　要：肺癌的传统治疗不尽人意,迫切需要探索新的治疗方法来打破这一瓶颈局面。免疫治疗是一种高特异性,低毒的新型治疗手段,其中阻断PD-1/PD-L1通路是最具有前景的治疗方向之一,目前大量研究报道PD-1和PD-L1抑制剂在晚期非小细胞肺癌治疗中取得显著疗效。然而PD-1/PD-L1抑制剂作为单药治疗或与其他抗肿瘤治疗联合在非小细胞肺癌中存在争议,本文将PD-1/PD-L1抑制剂在非小细胞肺癌中的治疗现状及最新进展进行综述。The traditional treatment of lung cancer is not satisfactory, so it is urgent to explore new therapy to break the bottleneck. Immunotherapy is a new treatment with low toxicity and high specificity. Suppressing the PD-I/PD-L1 pathway is considered as one of the most promising treatments. A number of studies reported that blockade of PD-1 and its ligand PD-L1 achieved favorable outcomes for advanced non-small cell lung cancer patients. Nonetheless, the anti-PD-1/PD-L1 antibody as monotherapy or in combination with other antineoplastic therapy in non-small cell lung cancer remains controversial. In this article, we reviewes the current state of research and advancement of PD-I/PD-L1 in the treatment of non-small cell lung cancer.

关 键 词：程序性死亡分子-1 程序性死亡配体-1 免疫治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]